L2 Asset Management’s Revolution Medicines RVMD Stock Holding History

L2 Asset Management’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$215K	Buy	+1,147	New	+$168K	0.02%	391

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

L2 Asset Management's RVMD Position: Q2 2026 in Review

L2 Asset Management opened a new position in Revolution Medicines (RVMD) in Q2 2026: 1,147 shares worth $215K. The stake represents 0.02% of the portfolio and ranks #391 among its holdings.

689 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

L2 Asset Management held 1,147 shares of Revolution Medicines worth $215K as of Q2 2026.
Revolution Medicines was a new L2 Asset Management position in Q2 2026.
Revolution Medicines made up 0.02% of L2 Asset Management's portfolio in Q2 2026, its #391 holding.
689 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on L2 Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.